Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of CF-301 plus standard antibacterial therapy versus placebo plus standard therapy for adult Staphylococcus aureus bacteremia including right-sided endocarditis
MOH_2017-12-11_002022Phase 2Completed
- Sponsor
- ContraFect Corporation
- Start
- Aug 2017
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcal bacteremia and right-sided infective endocarditis (RSIE) comparing CF-301 plus standard antibacterial therapy with Placebo plus standard antibacterial therapy (2 arms). Primary endpoint: Not reported in registry. Started Aug 2017; status: completed.
02
Drugs
exebacase
03
Conditions
Staphylococcal bacteremiaright-sided infective endocarditis (RSIE)
Beyond the preview
Go deeper on MOH_2017-12-11_002022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-11_002022.